Demand for Dyslipidemia Therapeutics Is Projected to Record 2.5% CAGR through 2028

Dyslipidemia Therapeutics Market Expected to Grow at 2.5% CAGR by 2028

According to a recently released Fact.MR study, revenues from dyslipidemia therapeutics market surpassed US$ 36 billion in 2018. Low-density lipoproteins held approximately two-thirds of revenues from dyslipidemia therapeutics worldwide in 2018. As high LDL levels have been associated with increased risks of heart attacks, strokes, and other cardiovascular problems in humans, governments around the world are launching various campaigns to raise awareness about the adverse impact of high LDL levels in the blood.

The growing prevalence of cardiovascular disorders worldwide has prompted individuals to effectively manage their LDL levels. To capitalize on the current trends prevalent in the dyslipidemia therapeutics market, pharmaceutical companies continue to strive towards developing new and improved therapies to lower LDL levels, and effectively manage the percentage of other lipids in the blood. A range of new treatments such as combination therapies, gene editing, and novel target drugs are under development, particularly for dyslipidemia therapeutics.

Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=2928

Dyslipidemia Therapeutics Market – Segmentation

Have a Query? Ask Our Industry Expert- https://www.factmr.com/connectus/sample?flag=AE&rep_id=2928

Statins Continue to Act as the Preferred Drug Class under Dyslipidemia Therapeutics

According to research findings, the sales of statins for dyslipidemia therapeutics is expected to surpass $20,000 million in 2019. Therefore, statins persist to remain the leading line of drugs recommended by doctors for the treatment of dyslipidemia. It is observed that statin drugs are considered useful in reducing LDL levels, due to their effectiveness in dropping LDL level approximately by 60%.

Furthermore, the use of statin drugs has been highlighted through clinical trials which represented a reduction of risk for cardiovascular diseases. In addition, its ability to support blood vessel relaxation also underwrites the lowering blood pressure in affected patients. This intelligent Fact.MR study later drops light on the growing prevalence of chemoprophylaxis, triggered by consumption of statins is further projected to encourage demand for dyslipidemia therapeutics in the near future.

Full Access of this Report Is Available at https://www.factmr.com/checkout/2928

Dyslipidemia Therapeutics Market – Additional Questions Answered

Apart from the aforementioned insights about the dyslipidemia therapeutics market, the report answers the following questions related to dyslipidemia therapeutics market:

• What region will hold the largest share of the dyslipidemia therapeutics market in 2019?
• What dyslipidemia drug type currently holds the pole position in terms of revenue?
• What dyslipidemia drug class will register the highest sales in 2019?
• What sales channel accounted for the most dyslipidemia therapeutic drug sales in 2018?
• What are the lucrative opportunities on offer in the dyslipidemia therapeutics market?

Competitive Scenario

Presently, the global dyslipidemia therapeutics market remains united, with major players accounting for close to 60% shares. The report highlights that co-promotion of dyslipidemia therapeutic drugs merged with local or regional players, new product launches, aggressive marketing, and high investments in R&D of novel drugs are seen as the primary drivers targeted by leading dyslipidemia therapeutics market performers. In the meantime, local players continue to emphasize on intensifying their manufacturing capacity in order to fulfill the growing demand for dyslipidemia drugs at the regional levels.

This assessment delivers a clear insight into the various market players together with comprehensive profiling. Some of the topmost companies operating in the dyslipidemia therapeutics market include Merck & Co., Novelion Therapeutics, Pfizer, Abbott Laboratories, Mylan, and Novartis AG.

Popular Healthcare Market Reports from Fact.MR

Orthopedic Implants Market– While an aging demographic and medical innovation continue to be key growth determinants for the orthopedic implants market, lack of exercise and obesity also contribute to a high rate of degenerative bone diseases, and osteoarthritis. This has driven demand for orthopedic implants across the globe.

Fetal and Neonatal Heart Monitor Market– Insufficient and improper nutrition delivery, a primary cause of preterm birth, has been lined with many health diseases and cardiovascular malignancies. An increase in the number of stillbirths on the coattails of preterm birth has raised concerns with regard to safety monitoring, such as heart rate monitoring.

Prefilled Syringes Market– With growing innovations in drug delivery systems, for instance, adoption of prefilled syringes, the administration of biologics has been convenient and effective. Novel drug delivery systems such as prefilled syringes have gained high traction as effective delivery systems, especially for injectable drugs.

About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com